The estimated Net Worth of Uneek Mehra is at least 5.7 百万$ dollars as of 16 December 2022. Mr Mehra owns over 2,241 units of Myovant Sciences Ltd stock worth over 5,468,738$ and over the last 3 years he sold MYOV stock worth over 234,270$.
Mr has made over 2 trades of the Myovant Sciences Ltd stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,241 units of MYOV stock worth 59,947$ on 16 December 2022.
The largest trade he's ever made was selling 9,243 units of Myovant Sciences Ltd stock on 16 September 2022 worth over 174,323$. On average, Mr trades about 1,914 units every 15 days since 2021. As of 16 December 2022 he still owns at least 202,696 units of Myovant Sciences Ltd stock.
You can see the complete history of Mr Mehra stock trades at the bottom of the page.
Uneek Mehra is the Chief Financial & Bus. Officer at Myovant Sciences Ltd.
Uneek's mailing address filed with the SEC is C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over 5,780,890$ worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth 2,001,605,371$ . The most active insiders traders include Sciences Ltd. Roivant、Global Investors Lp Viking ...、Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of 25,106,967$. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth 1,393,178,400$.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: